NCT03315039View on ClinicalTrials.gov

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

June 20, 2020

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Liposomal Annamycin

2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).

Trial Locations (4)

32610

University of Florida, Gainesville

44106

University Hospitals Cleveland Medical Center, Cleveland

79415

Southwest Cancer Center, Lubbock

92093

UC San Diego Health, La Jolla

Sponsors
All Listed Sponsors
lead

Moleculin Biotech, Inc.

INDUSTRY

NCT03315039 - Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter